Calluna Pharma

Next week, our CEO Mark Gaffney, and CMO Jonas Hallén, are going to be in London for Jefferies London Healthcare Conference 2024 taking place November 19-21.   This year’s event marks the 15th anniversary of the largest healthcare-dedicated conference in Europe and will provide the opportunity for global healthcare companies, investors, and VCs to get together to discuss investment opportunities and current trends driving healthcare in the U.S. and internationally.    If you're going to be in London next week, reach out to our team to learn more about Calluna's pipeline of first-in-class therapeutic antibodies targeting inflammation and fibrosis: https://lnkd.in/ePihiB4T    #JefferiesHealthcare #Pharma #Healthcare 

Today, while at #BIOEurope, our CEO Mark Gaffney, caught up with Amy Brown from BiotechTV for an insightful interview on Calluna's journey and scientific vision.    Mark shared how Calluna was founded with the aim to develop innovative therapies for serious inflammatory and fibrotic diseases, and delved into the cutting-edge science behind our lead program, CAL101 – a first-in-class therapeutic that targets the S100A4 protein, a Damage Associated Molecular Pattern (DAMP) implicated in a range of serious diseases. During the interview, Mark also discussed our promising Phase 1 data in both healthy volunteers and patients with psoriasis, underscoring CAL101’s potential as a novel therapeutic. With Phase 2 trials planned in idiopathic pulmonary fibrosis (IPF) and systemic sclerosis next year, we’re excited to advance this promising treatment for patients facing these debilitating conditions. A big thank you to BiotechTV and Amy Brown for highlighting our work at BIO-Europe. See the full interview: https://lnkd.in/gZUP8paq #Inflammation #Fibrosis #ClinicalTrial #Biotech

We’re #hiring a new SVP Discovery and Early Development in European Union. Apply today or share this post with your network.

Our CEO Mark Gaffney, and CMO Jonas Hallén are attending BIO-Europe in Stockholm, Sweden, next week, where the event marks 30 years of facilitating partnerships. Connect with our team at the event and register here: https://lnkd.in/dnuNZ2D Informa Connect See you there! #BIOEurope #Networking #Partnership 

We're excited to announce the successful completion of our Phase 1 clinical study for CAL101, Calluna’s lead drug candidate for the treatment of fibrotic and fibro-inflammatory diseases.   The first-in-human study demonstrated a favorable safety, pharmacokinetic and immunogenicity profile for CAL101 – a first-in-class mAb that targets S100A4, a DAMP protein implicated in serious and life-threatening diseases, such as idiopathic pulmonary fibrosis and systemic sclerosis.   For a summary of key results, read the full press release here: https://bit.ly/3AcXNfL #Fibrosis #Sclerosis #ClinicalTrial #Biopharma #Immunology

📢 We are hiring! We are looking to strengthen our team. Are you passionate about finance, efficiency, and making an impact? Then you may be the person we are looking for. As a hands-on and strategic 𝗖𝗼𝗻𝘁𝗿𝗼𝗹𝗹𝗲𝗿, you will play a key role in the financial management of Calluna Pharma and its subsidiaries. Your responsibilities will include: ➖ Overseeing day-to-day financial operations, including accounts payable, payroll, and general ledger activities across all locations ➖ Ensuring compliance with local and international regulations, including financial reporting, tax filings and audits ➖ Conducting internal financial reporting, and providing financial analysis and models to support decision-making ➖ Leading and managing the budgeting and long-range forecasting processes Learn more about the role here ➡️ https://lnkd.in/drjaMXXz This is a great time to join our team – learn more about our work on our website and send your application to Renate.birkeli@callunapharma.com #Hiring #NewRole #Finance #Biotech

We’re delighted to unveil our newly updated website, now offering enhanced features and deeper insights into our work. Here’s what you can explore: 🔬The science behind developing our therapeutics – Targeting upstream innate immune amplifiers, our first-in-class therapeutics modulate a wide range of disease-associated signaling pathways while ensuring a favorable safety profile. 📊Pipeline overview – Get a detailed look at our development programs and upcoming milestones. 👥Meet our team, board, and investors – Learn more about the experts behind our company’s growth. 📰Latest news – Stay updated with our press releases and company developments. Vacancies – Explore available roles and become part of our mission. Visit our website to check out the new features and learn more about how we’re developing groundbreaking therapeutics targeting inflammation and fibrosis: https://lnkd.in/e37y2VKy #NewWebsite #LifeSciences #Innovation 

📢 New announcement! We are excited to announce two key appointments as we continue advancing our mission to combat inflammatory and fibrotic diseases. ➡Mark Gaffney has joined Calluna as Chief Executive Officer and member of the Board. Bringing over 20 years of experience in corporate strategy, business development, and operations in both private and public biotechnology companies, Mark will lead the team through our next phase of growth as we progress our product candidates into the clinic. ➡Mark Altmeyer has joined Calluna as Independent Chair of the Board. Having served on the boards and as an advisor to several pharma and biotech companies, Mark brings extensive leadership experience to the team and will be instrumental in helping shape Calluna’s future. Together, their expertise strengthens Calluna’s leadership and reinforces our commitment to revolutionize treatment options and improve patient outcomes. Welcome to the team both! Read the full press release: https://lnkd.in/eeSVcKVT #Leadership #ExecutiveAppointment #PressRelease #LifeSciences #CEO #BoardChair

In a recent interview with Nordic Life Science News, our Co-Founder and CMO Jonas Hallén, MD, PhD, shares the vision and key factors behind the merger of Arxx Therapeutics and Oxitope Pharma. In this interview, Jonas discusses how the merger, backed by a successful Series A raise led by Forbion, Sarsia, p53, and Investinor, has positioned Calluna Pharma as a stronger player in the field of immunological disease therapies. Additionally, using Calluna Pharma’s success story as an example, Jonas discusses some key factors to consider for a successful merger, including: 💡 Leveraging complementary expertise and resources to create a robust clinical pipeline 💡 Building a unified team with shared goals and fostering a collaborative culture 💡 Aligning diverse teams from different countries and cultures through early team workshops and open communication Subscribe to read the full interview in September’s issue, page 77 (https://lnkd.in/epwjUPJa), and scroll through the carousel for more insights from the merger! 👇    #LifeSciences #Pharma #Merger 

Our SVP of Clinical Operations & Pharmacovigilance, Margrethe Sørgaard talks about her career and shares some insights for women aspiring to hold leadership positions within the industry, in an interview for Nordic Life Science news. In this interview, Margrethe shares how her extensive expertise in clinical development, pharmacovigilance, and leadership have helped shape her journey within the life science industry. With over 25 years of experience, Margrethe’s career has seen her lead teams at regulatory agencies and biotech companies, and now, at Calluna Pharma, she is supporting the development of therapies targeting chronic inflammation and fibrosis. Her advice to aspiring women leaders? 💡 Stay curious and passionate 💡 Don’t be afraid to challenge the norm 💡 Embrace authenticity and resilience in leadership Subscribe to read the full interview in September’s issue, page 34 (https://lnkd.in/epwjUPJa), and scroll through the carousel for more insights from Margrethe’s leadership journey! 👇 #Leadership #WomeninSTEM #Careeradvice